2011 – FDA issues Drug Safety Communication

Announcement Date: March 2, 2011

FDA issues Drug Safety Communication regarding an increased risk of low magnesium levels (hypomagnesemia) with symptoms of neurological, muscular and cardiac effects associated with PPI use.